Identifying Clinical Response to Daratumumab Therapy in Relapsed/refractory Multiple Myeloma Using a Patient-derived in Vitro Model

Overview

Journal EJHaem

Specialty Hematology

Date 2024 Feb 26

PMID 38406516

Authors

Niels van Nieuwenhuijzen

Marta Cuenca

Leonie Abbink

Margot Jak

Victor Peperzak

Monique C Minnema

Affiliations

Soon will be listed here.

Abstract

Response to daratumumab in patients with relapsed/refractory multiple myeloma is heterogeneous, and a reliable biomarker of response is lacking. We aimed to develop a method that identifies response to daratumumab therapy. Patient-derived MM cells were collected before start of daratumumab treatment and were cultured in a hydrogel-based culture system. The extent of antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro was associated with both clinical response and progression-free survival in corresponding patients. Together, our results demonstrate that in vitro sensitivity to daratumumab therapy in a hydrogel culture with primary MM cells might be used to identify patients most likely to benefit from treatment.

Citing Articles

Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient-derived in vitro model.

van Nieuwenhuijzen N, Cuenca M, Abbink L, Jak M, Peperzak V, Minnema M EJHaem. 2024; 5(1):141-146.

PMID: 38406516 PMC: 10887349. DOI: 10.1002/jha2.824.

References

de Weers M, Tai Y, van der Veer M, Bakker J, Vink T, Jacobs D . Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2010; 186(3):1840-8. DOI: 10.4049/jimmunol.1003032. View

van Nieuwenhuijzen N, Cuenca M, Abbink L, Jak M, Peperzak V, Minnema M . Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient-derived in vitro model. EJHaem. 2024; 5(1):141-146. PMC: 10887349. DOI: 10.1002/jha2.824. View

Offidani M, Corvatta L, More S, Nappi D, Martinelli G, Olivieri A . Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments. Front Oncol. 2021; 10:624661. PMC: 7928404. DOI: 10.3389/fonc.2020.624661. View

Walker Z, VanWyngarden M, Stevens B, Abbott D, Hammes A, Langouet-Astrie C . Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression. Blood Adv. 2020; 4(8):1628-1639. PMC: 7189287. DOI: 10.1182/bloodadvances.2019000122. View

Plesner T, Krejcik J . Daratumumab for the Treatment of Multiple Myeloma. Front Immunol. 2018; 9:1228. PMC: 5994592. DOI: 10.3389/fimmu.2018.01228. View

Wensink G, Elias S, Mullenders J, Koopman M, Boj S, Kranenburg O . Patient-derived organoids as a predictive biomarker for treatment response in cancer patients. NPJ Precis Oncol. 2021; 5(1):30. PMC: 8042051. DOI: 10.1038/s41698-021-00168-1. View

Braham M, Alblas J, Dhert W, Oner F, Minnema M . Possibilities and limitations of an three-dimensional bone marrow model for the prediction of clinical responses in patients with relapsed multiple myeloma. Haematologica. 2019; 104(11):e523-e526. PMC: 6821629. DOI: 10.3324/haematol.2018.213355. View

Lokhorst H, Plesner T, Laubach J, Nahi H, Gimsing P, Hansson M . Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015; 373(13):1207-19. DOI: 10.1056/NEJMoa1506348. View

Papadimitriou K, Kostopoulos I, Tsopanidou A, Orologas-Stavrou N, Kastritis E, Tsitsilonis O . Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma. Cancers (Basel). 2020; 12(8). PMC: 7463609. DOI: 10.3390/cancers12082006. View

10.

Casneuf T, Xu X, Adams 3rd H, Axel A, Chiu C, Khan I . Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Adv. 2018; 1(23):2105-2114. PMC: 5728278. DOI: 10.1182/bloodadvances.2017006866. View

11.

Cuenca M, van Nieuwenhuijzen N, Moesbergen L, Bloem A, Minnema M, Peperzak V . Targeting B-cell maturation antigen increases sensitivity of multiple myeloma cells to MCL-1 inhibition. Haematologica. 2021; 107(4):980-983. PMC: 8968894. DOI: 10.3324/haematol.2021.279517. View

12.

Kitadate A, Kobayashi H, Abe Y, Narita K, Miura D, Takeuchi M . Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients. Haematologica. 2019; 105(1):e37-e40. PMC: 6939519. DOI: 10.3324/haematol.2019.219683. View

13.

Usmani S, Weiss B, Plesner T, Bahlis N, Belch A, Lonial S . Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016; 128(1):37-44. PMC: 4937359. DOI: 10.1182/blood-2016-03-705210. View

14.

Mosquera Orgueira A, Gonzalez Perez M, Diaz Arias J, Antelo Rodriguez B, Alonso Vence N, Bendana Lopez A . Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data. Leukemia. 2021; 35(10):2924-2935. DOI: 10.1038/s41375-021-01286-2. View

15.

Meyer S, Leusen J, Boross P . Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer. MAbs. 2014; 6(5):1133-44. PMC: 4622586. DOI: 10.4161/mabs.29670. View

16.

Lara S, Heilig J, Virtanen A, Kleinau S . Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma. BMC Cancer. 2022; 22(1):678. PMC: 9210731. DOI: 10.1186/s12885-022-09772-1. View

17.

Vangsted A, Helm-Petersen S, Cowland J, Jensen P, Gimsing P, Barlogie B . Drug response prediction in high-risk multiple myeloma. Gene. 2017; 644:80-86. DOI: 10.1016/j.gene.2017.10.071. View

18.

Nijhof I, Casneuf T, van Velzen J, van Kessel B, Axel A, Syed K . CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016; 128(7):959-70. DOI: 10.1182/blood-2016-03-703439. View

19.

Pawlyn C, Davies F . Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood. 2018; 133(7):660-675. PMC: 6384187. DOI: 10.1182/blood-2018-09-825331. View